Seeking Alpha

Microcap biotech firm Neuralstem (CUR +0.6%) says the FDA has signed off for the company to...

Microcap biotech firm Neuralstem (CUR +0.6%) says the FDA has signed off for the company to advance to Phase Ib in the ongoing clinical trial of its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs